@article{9110969eb9334e40a1a827a7ea859331,
title = "Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer",
abstract = "Aim: Evaluate quality of life (QoL) in patients with advanced non-small cell lung cancer treated with second or third line nab-paclitaxel ± durvalumab. Patients & methods: Longitudinal QoL was assessed using Lung Cancer Symptom Scale, EuroQoL Five-Dimensions Five-Levels and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core. Results: QoL was generally stable through eight treatment cycles (both arms). Clinically meaningful improvement from baseline was noted in Lung Cancer Symptom Scale (overall constitutional score and three-item index [nab-paclitaxel + durvalumab]) and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30-item core (global health status/QoL and emotional functioning [both arms] and pain [nab-paclitaxel + durvalumab]) analyses. EuroQoL Five-Dimensions Five-Levels domains were stable/improved or completely resolved at least once in 19-56% and 9-51% of patients, respectively. Conclusion: While QoL trends were promising, additional data are required to support these regimens in this setting.",
keywords = "EORTC QLQ-C30, EQ-5D-5L, durvalumab, lung cancer symptom scale, nab-paclitaxel, non-small cell lung cancer, quality of life",
author = "{Ponce Aix}, Santiago and Denis Talbot and Ramaswamy Govindan and Dols, {Manuel Cobo} and Postmus, {Pieter E.} and Conrad Lewanski and Jaafar Bennouna and Fischer, {Juergen R.} and Oscar Juan-Vidal and Stewart, {David J.} and Andrea Ardizzoni and Rafia Bhore and Marianne Wolfsteiner and Martin Reck and Ong, {Teng Jin} and Daniel Morgensztern",
note = "Funding Information: This study was supported by Celgene Corporation, Summit, NJ, USA. SP Aix, M Cobo Dols , JR Fischer and O Juan-Vidal report nothing to disclose. D Talbot has served on an advisory board for AstraZeneca, Boehringer Ingelheim, Celgene, Pfizer, Eli Lilly, No-vartis, Clovis and Roche; has been a consultant for Boehringer Ingelheim, Celgene and Achilles; and reports honoraria from Pfizer, Novartis and Celgene. R Govindan has served on an advisory board for AbbVie, AstraZeneca, Baxalta, Boehringer Ingelheim, Cel-gene, Merck, MSK, Pfizer and Roche; has been a consultant for AbbVie, ARIAD, Astellas, Bristol-Myers Squibb, Genentech and INC Research; and reports honoraria from AbbVie. PE Postmus has served on an advisory board for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Clovis, Janssen, MSD and Roche. C Lewanski has been a consultant for Eli Lilly. J Bennouna has served on an advisory board for Amgen, AstraZeneca, Bristol-Myers Squibb and Novartis; and reports symposium for AstraZeneca, Novartis and Roche. DJ Stewart has served as a consultant, has served on advisory boards and has received honoraria from Roche Canada, Boehringer Ingelheim Canada, Merck Canada, AstraZeneca Canada, Bristol-Myers Squibb Canada and Exactis and clinical trials support from Boehringer Ingelheim, AstraZeneca, Novartis, Bristol-Myers Squibb and Celgene. A Ardizzoni reports honoraria from Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and MSD. R Bhore and TJ Ong report employment or leadership position and stock ownership at Bristol-Myers Squibb. M Wolfsteiner has served as a contracted medical reviewer for Celgene Corporation. M Reck has served on an advisory board for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Lilly, MSD, Pfizer and Roche. D Morgensztern has served on an advisory board for AbbVie, Bristol-Myers Squibb, Takeda, Pharma Mar and Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Publisher Copyright: {\textcopyright} 2020 Celgene.",
year = "2020",
month = apr,
doi = "10.2217/fon-2019-0796",
language = "English",
volume = "16",
pages = "749--762",
journal = "Future Oncology",
issn = "1479-6694",
number = "12",
}